<DOC>
	<DOCNO>NCT00108823</DOCNO>
	<brief_summary>The purpose trial study effect roflumilast lung function parameter indicative hyperinflation patient COPD .</brief_summary>
	<brief_title>The HERO-study : Effects Roflumilast Patients With COPD ( Chronic Obstructive Pulmonary Disease ) ( BY217/M2-121 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Main Written inform consent Patients history chronic obstructive pulmonary disease least 12 month define GOLD ( Global Initiative Obstructive Lung Diseases ) criterion ( 2003 ) Age ≥ 40 year FEV1/FVC ratio ( postbronchodilator ) ≤ 70 % FEV1 ( postbronchodilator ) ≤ 65 % predict FRC ( postbronchodilator ) ≤ 120 % predict Clinically stable COPD within 4 week prior baseline visit ( B0 ) . Availability chest xray date maximum 6 month prior study baseline visit ( B0 ) willingness chest xray perform visit ( B0 ) . Main COPD exacerbation indicate treatment systemic glucocorticosteroids stop least 4 week prior baseline visit ( B0 ) Non smoker , current smoker exsmoker ( smoke cessation least one year ago ) smoke history &lt; 10 pack year Suffering concomitant disease might interfere study procedure evaluation Lower respiratory tract infection resolve 4 week prior baseline visit ( B0 ) Diagnosis asthma and/or relevant lung disease ( e.g . history bronchiectasis , cystic fibrosis , bronchiolitis , lung resection , lung cancer , interstitial lung disease [ e.g . fibrosis , silicosis , sarcoidosis ] , active tuberculosis ) Current participation pulmonary rehabilitation program completion pulmonary rehabilitation program within 2 month precede baseline visit ( B0 ) . Known alpha1antitrypsin deficiency Need long term oxygen therapy define ≥ 15 hours/day Clinically relevant abnormal laboratory value suggest unknown disease require clinical evaluation ( assessed investigator ) Known infection HIV , active hepatitis and/or liver insufficiency Diagnosis history cancer ( basal cell carcinoma ) recurrence within 5 year prior study start Clinically significant cardiopulmonary abnormality ( diagnose clinically xray/ECG ) relate COPD require evaluation Pregnancy , breast feeding , oocyte donation oocyte implantation plan trial The female patient childbearing potential use willing continue use medically reliable method contraception entire study duration , oral , injectable , implantable contraceptive , intrauterine contraceptive device , unless surgically sterilized/hysterectomized postmenopausal &gt; 1 year criterion consider sufficiently reliable investigator individual case Participation another study ( use investigational product ) within 30 day precede baseline visit ( B0 ) reentry patient already enrol trial Suspected inability unwillingness comply study procedure Alcohol drug abuse Inability follow study procedure due , example , language problem psychological disorder Use prohibit drug Suspected hypersensitivity study medication and/or contraindication ingredient study medication ( roflumilast ) rescue medication</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>